Exclusive Summary

• First-in-class dual-targeting mechanism: UB345 targets both IL-6R and TNF-α concurrently, producing synergistic immune suppression that potentially overcomes non-response and resistance seen in monotherapies.
• Strategic clinical indication layout: It bridges highly lucrative specialist markets (Uveitis, NMOSD) with massive, untapped blue-ocean spaces like dental caries microenvironment immunology.
• Robust pre-clinical PoC: Pre-clinical in vitro validations show excellent relative binding affinity, receptor blockade, and dual-bioactivity that strongly compete with reference antibodies.
• Compelling asset for global out-licensing: By filling the pipeline gap for synergistic biologics and novel mucosal applications, UB345 presents a highly attractive technical transfer and co-development candidate for global Big Pharma.

Asset Materials

Contact Us for Full Materials